In addition to numerous positive vaccine reports over the past few days, researchers in the USA are now promoting another positive corona news: they claim to have developed a drug that prevents the spread of the virus. That would be a real turning point!
Scientists at Georgia State University in Atlanta, USA, are on the path to a bigger cause: According to the Italian news agency Ansa, they have developed an antiviral drug that prevents the transmission of the corona virus in the journal “Nature Microbiology”. Special feature: The active ingredient can be taken orally.
Corona: Molnupiravir can prevent the spread of the virus
The agent, which has so far only been tested on ferrets, prevents the virus from reproducing in the body within 24 hours. So it cannot spread throughout the body.
According to scientists, the data can be transmitted to humans – the first studies with volunteers are already underway. This means that people with coronavirus will no longer be infected after taking the drug molnupiravir within 24 hours at the latest time.
According to the researchers, this could have multiple effects: it would prevent a serious course of disease, significantly reduce the incidence of epidemics, thereby speeding up the control of local epidemics, and mitigate the ship’s emotional and social repercussions.
You may also be interested in: Up to 40 percent affected! Italian researchers report a new corona symptom
The agent is the first oral drug that can rapidly block the transmission of SARS-Covy-2, said Richard Plumber, one of the scientists involved in the research. Molnupiravir was able to “change the game”.
This is how the researchers tested the drug
But how exactly does it work? The researchers shut down several ferrets and healthy concoctions that affected Covid-19. Some sick animals received molecules, another placebo.
Subsequent testing revealed that the ferrets treated with molluscum contagiosum did not transmit the disease, but untreated animals transmitted the virus to others.
Molnupiravir was already used on an experimental basis during the corona pandemic
The drug, which is said to work in a similar way to rendevivir, was first developed to treat influenza. However, as early as April 2020, a study found that molnupiravir can prevent and reduce severe lung damage in corona-infected mice.
The product from Ridgeback Biotechnics manufacturer is currently in Phase II / III clinical study. It will take up to half of next year until all the obstacles required for approval are removed and utilized.